ArticleFrontiers in pharmacology2025

Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin.

Fei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.